Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Epratuzumab Y-90

Drug Profile

Epratuzumab Y-90

Alternative Names: 90Y-DOTA-hLL2; 90Y-Epratuzumab; 90Y-hLL2; 90Y-hLL2 IgG; Anti-CD22 monoclonal antibody LL2-Y-90; hCD22-Y-90; IMMU-102; Monoclonal antibody LL2-Y-90; Y-90 epratuzumab tetraxetan; Yttrium-90 epratuzumab tetraxetan; Yttrium-90-labelled epratuzumab

Latest Information Update: 24 Oct 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Immunomedics
  • Developer Immunomedics; Nantes University Hospital; Weill Cornell Medical College
  • Class Antineoplastics; Monoclonal antibodies; Radiopharmaceuticals
  • Mechanism of Action Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Diffuse large B cell lymphoma; Follicular lymphoma; Non-Hodgkin's lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma

Most Recent Events

  • 02 Dec 2020 Immunomedics terminates a phase I/II trial for Non-Hodgkin's lymphoma (Second-line therapy or greater, Combination therapy) in USA as no subjects were enrolled (NCT01101581)
  • 02 Dec 2020 Immunomedics terminates a phase I/II trial for Non-Hodgkin's lymphoma (Second-line therapy or greater, Monotherapy) in USA as no subjects were enrolled (NCT01101581)
  • 23 Oct 2020 Immunomedics has been acquired by Gilead Sciences
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top